tomography scanning and magnetic resonance angiography are also used. 1, 13, 16, 31 Two-thirds of DVT/PE events in patients with brain tumors occur within 6 weeks after the patient has undergone craniotomy. 26 Thus, identification at the time of surgery of those patients at high risk of developing a DVT/PE might permit more aggressive prophylactic treatment to prevent thrombotic complications, limit the overall morbidity and mortality rates associated with DVT/PE, improve the quality of remaining survival time, and reduce treatment costs.
Clinical Material and Methods
We conducted a retrospective review of the medical records of 488 patients in our brain tumor registries between the years 1988 and 1995. Fifty-seven (12%) of the 488 patients had symptomatic DVT, PE, or both. The DVT was diagnosed by duplex sonography (all 57 patients), whereas patients suspected of having a PE had either positive V/Q scanning (five patients), pulmonary angiography (two patients), or both (three patients). In 24 (42%) of these 57 cases, pathological specimens were retrievable and, hence, available for study. Forty-five patients were lost to follow-up review. Of the remaining 386 patients in whom no recorded thrombotic complications occurred, there were 50 slides of pathological specimens that could be retrieved for review. Of these 50, 25 were selected at random by a blinded observer to represent the control group (with knowledge of the reported histological classification, but without knowledge of patient identity). Intraluminal thrombosis (ILT) was graded semiquantitatively (the grade was assigned according to the most severely thrombosed vessel seen in the sample). A value of zero was assigned if none was seen and 1, 2, or 3 if the thrombus occluded up to one-third, two-thirds, or the whole tumor vessel, respectively ( Table 1 ). The necrotic component and extent of endothelial proliferation immediately adjacent to the thrombosed vessel were evaluated and graded as mild, moderate, or severe ( Table 1) .
The histological characteristics of the tumors, as seen in biopsy specimens stained by hematoxylin and eosin ( Fig. 1) , were graded by two blinded independent neuropathologists who used the new World Health Organization classification of brain tumors. 19 A statistical analysis of clinical and demographic patient characteristics was conducted to determine factors associated with the development of DVT and PE. Odds ratios were calculated and the statistical significance of the associations found were assessed using Fisher's exact test.
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Results
Fourteen patients (58%) who developed DVT/PE experienced a clinically evident thrombotic event within 6 weeks of their surgical procedure ( Table 2) . None of the patients who suffered DVT/PE were receiving prophylactic therapy at the time of the thrombotic event. Limb paresis was recorded in 14 patients (58%) in the study group and in 15 patients (60%) in the control group. However, the severity of weakness and the length of immobility was difficult to quantify uniformly from the records.
Twenty-four of our 57 patients who had documented DVT/PE and 25 patients with brain tumors but no DVT/ PE (control group) had pathological specimens retrievable for evaluation. Eighteen patients (75%) in the study group and 17 patients (68%) in the control group underwent cytoreductive surgery lasting an average of 3.1 and 2.7 hours, respectively ( Table 2 ). All remaining patients (25% in the study group and 32% in the control group) underwent biopsy sampling without resection. The degree of resection (whether biopsy or cytoreductive surgery) had no statistically significant effect on the development of DVT/PE. The median age of those patients who developed DVT/PE was 48.7 years, with glioblastoma multiforme accounting for the majority of the pathological diagnoses (71%). High-grade oligoastrocytoma and lymphoma accounted for 8% each, whereas anaplastic astrocytoma, gliosarcoma, and primitive neuroectodermal tumor accounted for 4% each. The control group of patients without DVT had the same number of cases of glioblastoma multiforme (17) as the study group. Retrospective examination of patient files showed that sizes of tumor in both groups (greatest diameter or volumetric measurements) were inconsistently recorded. The median age of the control group was 53 years, with a stronger male representation. However, age and gender differences were not significantly associated with DVT/PE. Varying grades of necrosis, endothelial proliferation, and perivascular lymphocytic infiltrates were observed among the biopsy samples obtained in patients with DVT/PE and in the control group of 25 patients without DVT/PE ( Grade 2 (moderate) in seven patients and Grade 3 (severe) in seven. The combination of ILT and necrosis was seen in only three patients in the control group without DVT/ PE and ILT was Grade 1 in each of these (Table 2) . Univariate statistical analysis was performed to identify predictive factors for DVT/PE. 15 The results of the statistical analysis are shown in Fig. 2 , indicating positive predictors (risk factors) and negative predictors (protective factors). The plotted odds ratios quantify the increased or decreased risk of DVT/PE with each of the particular characteristics in question. Trailing asterisks identify statistically significant associations. The presence of any ILT, whether mild or severe, was strongly associated with the development of DVT/PE. The odds ratio associated with the presence of ILT was 17.8 with a 95% confidence interval ranging from 4 to 79.3. This odds ratio provides an estimate of the relative increase in risk of developing DVT/PE when ILT of brain tumor vessels is present. Thus, if a patient's tumor has ILT, he or she has an approximately 20-fold greater chance of developing DVT/PE. In case-control retrospective studies, such as this one, this is the best estimate that can be obtained of the relative risk. The fact that the entire confidence interval is elevated here emphasizes the increased risk of developing DVT/PE if ILT of brain tumor vessels is present. In patients with higher levels of ILT (moderate to severe), the odds ratio increases still further (26.3 with p = 0.0016). Thus, greater amounts of ILT appear to be associated with a higher risk of DVT/PE than lesser amounts of ILT.
Moderate-to-marked lymphocytic infiltrate and moderate-to-severe necrosis were also predictive of increased risk, although the strength of the associations was less than that for ILT (Fig. 2) . Women were more likely than men to develop DVT/PE, but the difference did not reach statistical significance. The presence of moderate-tosevere endothelial proliferation and age older than 50 years were associated with the absence of development of DVT/PE; however, neither of these associations was statistically significant.
In an attempt to rule out the more common confounding relationships that might have relevance to DVT causality, we analyzed limb paresis, extent of surgery (biopsy compared with resection), and duration of surgery in DVT/PE cases compared with the same factors in control patients. None of these factors were found to differ significantly between the two groups. The proportion of patients who underwent procedures lasting 3.5 hours or longer was larger in the study group, 58% compared with 32%, a difference which again fell short of statistical significance (p = 0.09). Therefore, limb paresis, extent of surgical resection, and duration of surgery-factors common to the development of DVT/PE-were not the basis for differences between the study and control groups.
Discussion
The occurrence of DVT/PE events in this retrospective series was only 12%, somewhat lower than rates reported in other series. 26 This can be accounted for, in part, by the number of patients (45) who were lost to follow-up review. In addition, prophylactic measures were taken by using pneumatic compression stockings in the perioperative period in all patients. The DVT/PE studies in patients with glioma have revealed an association between paresis of an arm or leg and venous thromboembolism. 24 Sequential venous compressive devices were used in all patients intraoperatively and postoperatively until they became ambulatory. The percentage of patients with limb paresis was approximately equal in the two groups. The severity of limb paresis and the length of immobility were difficult to analyze from this retrospective material.
Other tumor-specific factors that might be associated with systemic thromboembolism are less well studied. In one study, expression of antithrombin III was reduced in glioblastoma multiforme and anaplastic astrocytoma cap-
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Intraluminal thrombosis in brain tumor vessels illaries compared with those in normal brain. 18 Thus, local factors governing the level of antithrombotic activity such as antithrombin III expression could play a role in ILT formation. Conditioned culture media from human glioblastoma tumor explants and U251 glioma cells contain vascular endothelial growth factor, 10 which increases von Willebrand factor release 8 and thromboplastin activity in human endothelial cells. 9 Both of these actions could contribute to the hypercoagulability seen in patients with malignant brain tumors, which could lead to focal ILT of tumor vessels.
Necrosis frequently coexists with abundant endothelial proliferation in malignant glioma. This necrosis is thought to result from the inability of tumor angiogenesis to keep pace with tumor proliferation. 20 However, in our study ILT without necrosis occurred in only a single patient with DVT (Case 18, Table 2 ). This emphasizes the statistically significant association of ILT with the development of DVT and suggests that necrosis seen in glioblastoma may result in part from thrombosis in tumor vessels with subsequent tumor infarction.
Although a strong association between brain tumor and thromboembolic complications has been confirmed previously, 17, 23, 25 the specific pathophysiological mechanism responsible for producing the hemostatic alterations has not been clearly elucidated. Three general mechanisms are postulated to account for tumor-induced activation of the coagulation system and include: 1) secretion of activating molecules by the tumor or exposure of cell surface proteins capable of activating the coagulation system; 2) nonspecific activation of the coagulation system by the release of intracellular tissue thromboplastin; and 3) activation of the host immune system causing induction of procoagulant activity in lymphoid cells. 12 Cytokines represent one large group of proteins that are involved in cellular communication. There are several well-recognized categories of cytokines, 3 including interferons, interleukins, tumor necrosis factors (TNF␣ and TNF␤), and others.
11 Some malignancies synthesize cytokines that induce a marked increase in cell-associated tissue factor activity by the endothelium or circulating host monocytes or macrophages, resulting in activation of coagulation. 21 The TNF␣ expressed by malignant brain tumors may be involved in this observed hypercoagulable state. This cytokine has a broad spectrum of target cells including vascular endothelial cells, which it induces to express adhesion molecules (endothelial leukocyte and intercellular adhesion molecules) to bind neutrophils and monocytes to the endothelial cell.
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Bethea, et al., 6 have demonstrated that human glioma cell lines can produce TNF␣, whereas Bauer and colleagues 4 have found that intravenous infusion of TNF␣ promotes clot formation along the endothelial cell wall. The TNF␣ can activate the extrinsic system of coagulation directly by inducing the expression of "tissue factor," which is the ligand for factor VII on monocytes and endothelial cells. 30 Experimentally, the incubation of vascular endothelial cells with TNF␣ suppresses their fibrinolytic capacity by decreasing the production of tissuetype plasminogen activator and increasing the synthesis of type 1 plasminogen activator inhibitor, favoring the coagulant properties of the vascular endothelium. 27 Tumor necrosis factor alpha also causes internalization of thrombomodulin by endothelial cells. Thrombomodulin, when bound to thrombin, is a potent activator of protein C, which in turn inactivates factors VIII and Va, favoring thrombosis. 14 The choice of optimum prophylactic measures to prevent thrombosis in neurosurgical patients remains controversial. It appears that patients with brain tumors have a higher risk of thrombotic complications than the general neurosurgical population and that more aggressive prophylactic measures may be warranted. It is generally conceded that routine DVT surveillance is not cost effective for the general neurosurgical population or for patients with brain tumors. Our preliminary observation that the presence of ILT in biopsy specimens obtained in patients with brain tumors can predict a significantly greater risk of thromboembolic complication (up to 20-fold) suggests that this subset of patients may be at sufficiently high risk to justify routine DVT surveillance with noninvasive monitoring such as lower-extremity duplex imaging. Alternatively, patients found to have ILT may represent a subgroup that requires more aggressive prophylactic treatment for DVT, such as anticoagulant therapy. These issues are currently being investigated in prospective studies with controls for prophylactic interventions.
We can infer from our data that an active search for and analysis of ILT in all malignant brain tumor samples should be conducted routinely. This preliminary observation can be made by the pathologist at the "reading" of the "frozen section," while the patient is in the operating room. The finding of ILT can then be confirmed and scored the next day by examining permanent slides of tissue stained by hematoxylin and eosin, allowing those who are managing the patient postoperatively to decide whether Doppler studies of the lower extremities or more aggressive DVT prophylaxis should be instituted.
